資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/31650
|
| 標題: | Cephalosporin-Glycopeptide Combinations for Use against Clinical Methicillin-Resistant Staphylococcus aureus Isolates: Enhanced In vitro Antibacterial Activity |
| 作者: | Tang, Hung-Jen
Lai, Chih-Cheng
Chen, Chi-Chung
Zhang, Chun-Cheng
Weng, Tzu-Chieh
Yu, Wen-Liang
Chen, Hung-Jui
Chiu, Yu-Hsin
Ko, Wen-Chien
Chuang, Yin-Ching |
| 貢獻者: | Chi Mei Med Ctr, Dept Med
Chia Nan Univ Pharm & Sci, Dept Hlth & Nutr
Chi Mei Hosp Liou Ying, Dept Intens Care Med
Chi Mei Med Ctr, Med Res
Chi Mei Hosp Liou Ying, Med
Natl Cheng Kung Univ Hosp, Dept Internal Med
Natl Cheng Kung Univ Hosp, Ctr Infect Control
Natl Cheng Kung Univ, Coll Med, Dept Med |
| 關鍵字: | glycopeptides
cefazolin
cefmetazole
cefotaxime
cefepime
combination therapy
synergism
MRSA |
| 日期: | 2017-05-18 |
| 上傳時間: | 2018-11-30 15:51:34 (UTC+8) |
| 出版者: | Frontiers Media Sa |
| 摘要: | The empirical combination of both a beta-lactam and glycopeptide to counter potential staphylococcal pathogens may improve the clinical outcomes for cases of Staphylococcus aureus bacteremia. We reported comparative in vitro studies of combination effects of different cephalosporins (i.e., cefazolin, cefmetazole, cefotaxime, and cefepime) combined with glycopeptides for 34 randomly selected methicillin-resistant S. aureus (MRSA) isolates by three methods, including the checkerboard, time-killing, and combination MIC measurement methods. Thirteen SCCmec type III isolates with a cefazolin MIC of >= 128 mu g/mL were classified as the high-cefazolin MIC (HCM) group, whereas 13 SCCmec type IV and 8 SCCmec type V isolates were classified as the low-cefazolin MIC (LCM) group. With the checkerboard method, synergism was present for vancomycin-based combinations at 30.8-69.2 and 13.6-66.7%, as well as teicoplanin-based combinations of 38.5-84.6 and 0-47.6%, of the HCM and LCM isolates, respectively. No antagonism was noted. The in vitro inhibitory activity was evident even at a low concentration of 1/512x MIC of cephalosporin combined with sub-inhibitory concentrations (1/2x MIC) of a glycopeptide. With time-killing assays, synergism was noted at 1/2x or lx susceptible breakpoint concentrations (SBCs) of a cephalosporin combined with 1/4 or 1/2 MIC of a glycopeptide. In the presence of 1/2 SBC of a cephalosporin, vancomycin or teicoplanin MICs decreased an average of 2.0- to 6.6- or 1.6- to 5.5-fold, respectively. With 8 mu g/mL cephalosporin, the decline of glycopeptide MICs was most obvious in the presence of cefmetazole. In conclusion, cephalosporin-glycopeptide combinations at clinically achievable concentrations can exhibit in vitro synergistic antibacterial activity against clinical MRSA isolates. Such combinations require more clinical data to support their application for use in human MRSA infections. |
| 關聯: | Frontiers In Microbiology, v.8, pp.884 |
| 顯示於類別: | [保健營養系(所) ] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| fmicb.2017.00884.pdf | | 1290Kb | Adobe PDF | 0 | 檢視/開啟 | | index.html | | 0Kb | HTML | 1403 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
